



Application of Viral Vectors for Vaccine Development

Guest Editor:

Prof. Dr. Fei Guo

Institute of Pathogen Biology,
and Center for AIDS Research,
Chinese Academy of Medical
Sciences & Peking Union Medical
College, Beijing, China

Deadline for manuscript
submissions:

closed (1 May 2024)

Message from the Guest Editor

Dear Colleagues,

In the quest to develop novel vaccines, DNA, mRNA, and viral vector platforms have been employed. Both traditional and genetically engineered vaccines have contributed to the control of infectious disease pandemics, such as COVID-19. However, viral vectors, which can induce robust responses, have attracted increased attention in recent years. Viral vector vaccines have been applied in both pre-clinical and clinical trials as vaccines against a variety of infectious diseases, such as HIV-1, and SARS-CoV-2, etc.

This Special Issue will provide a platform through which to discuss provision of enhanced vaccine designs, research works, and experimental results regarding the development of viral vector vaccines for both infectious and non-infectious diseases. We are pleased to invite you to contribute to this Special Issue with original research articles and reviews that focusing topics that include the following:

- Viral vector vaccine development and efficacy evaluation
- Vaccine technology
- Cancer vaccine
- Multiple vaccine technological platforms
- Protective mechanisms
- Immune response to vaccines



mdpi.com/si/171072

Prof. Dr. Fei Guo
Guest Editor

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)